6882-74-2

Usage

Uses

Used in Pharmaceutical Industry:
4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE is used as a chemical building block for the synthesis of bioactive compounds due to its ability to contribute to the development of drugs with antiviral, antibacterial, and antifungal properties.
Used in Antiviral Applications:
In the field of antiviral drug development, 4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE is used as a key component in the creation of antiviral agents, leveraging its chemical structure to inhibit viral replication and reduce the severity of viral infections.
Used in Antibacterial Applications:
4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE is utilized as a component in the synthesis of antibacterial drugs, where it aids in the development of compounds that can effectively combat bacterial infections.
Used in Antifungal Applications:
4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE is also used in the formulation of antifungal medications, serving as a crucial part of the molecular structure that targets and inhibits fungal growth.
Used in Neurological Disorder Treatment:
4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE is studied for its potential role in the treatment of neurological disorders, where it may contribute to the development of therapeutics that address specific neurological conditions.
Used in Cancer Treatment:
In oncology, 4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE is being investigated for its potential to be incorporated into cancer treatments, possibly enhancing the effectiveness of existing therapies or providing new avenues for intervention against cancer cells.

InChI:InChI=1/C6H9N3.ClH/c1-2-7-3-6-5(1)8-4-9-6;/h4,7H,1-3H2,(H,8,9);1H

Upstream product

• 50-00-0 formaldehyd 
• 56-92-8 histamine dichloride 
• 51-45-6 histamine 
• 55-36-7 histamine dihydrochloride 
• 55-36-7 2-(1H-imidazol-5-yl)ethanamine hydrochloride 
• 109-87-5 Dimethoxymethane 

Downstream Products

• 1202800-68-7 1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester 
• 1421503-53-8 2-iodo-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester 
• 1421503-55-0 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazol-3-yl]-1-(2-trimethylsilanyl-ethoxymethyl)-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester 
• 1421503-52-7 6,7-dihydro-4H-imidazo[4,5-c]pyridine-1,5-dicarboxylic acid di-tert-butyl ester 
• 1312784-89-6 tert-butyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 
• 1312784-88-5 tert-butyl 3-methyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate 
• 87673-88-9 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 
• 64403-25-4 3-methyl-3,4,6,7-tetrahydro-5H-imidazo<4,5-c>pyridine 

Relevant academic research and scientific papers

Tetrahydroimidazo[4,5-c]pyridine-based inhibitors of porphyromonas gingivalis glutaminyl cyclase

Periodontitis is a severe yet underestimated oral disease. Since it is linked to several systemic diseases, such as diabetes, artheriosclerosis, and even Alzheimer’s disease, growing interest in treating periodontitis has emerged recently. The major cause of periodontitis is a shift in the oral microbiome. A keystone pathogen that is associated with this shift is Porphyromonas gingivalis. Hence, targeting P. gingivalis came into focus of drug discovery for the development of novel antiinfective compounds. Among others, glutaminyl cyclases (QCs) of oral pathogens might be promising drug targets. Here, we report the discovery and structure–activity relationship of a novel class of P. gingivalis QC inhibitors according to a tetrahydroimidazo[4,5-c]pyridine scaffold. Some compounds exhibited activity in the lower nanomolar range and thus were further characterized with regard to their selectivity and toxicity.

BACTERIAL GLUTAMINYL CYCLASES AND INHIBITORS THEREOF FOR USE IN THE TREATMENT OF PERIODONTITIS

The present invention relates to bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis and related conditions, and provides a bacterial glutaminyl cyclase (bacQC); an antibody which recognizes the bacQC, a method for identifying an inhibitor of the bacQC; a compound according to Formula (I); a pharmaceutical composition comprising a bacQC inhibitor compound; a bacQC inhibitor compound and/or a pharmaceutical composition for use in a method for treatment of the human or animal body, for use in a method for therapy or prophylaxis of a bacterial infection, and for use in a method for therapy and/or prophylaxis of an acute, chronic or recurrent periodontal disease.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

Synthesis and structure based optimization of novel Akt inhibitors

Based on a high throughput screening hit, pyrrolopyrimidine inhibitors of the Akt kinase are explored. X-ray co-crystal structures of two lead series results in the understanding of key binding interactions, the design of new lead series, and enhanced pot

4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives

New 4,5,6,7-tetrahydroimidazo-[4,5-c]-pyridine derivatives are disclosed, and more particularly derivatives of Formula I STR1 where R1 is hydrogen or an alkyl having from 1 to 4 carbon atoms; R2 is hydrogen, an alkyl having from 1 to 4 carbon atoms, a cycloalkyl having from 3 to 6 carbon atoms, phenyl or a heterocycle; R3 is hydrogen, a saturated or unsaturated straight or branched alkyl having from 1 to 6 carbon atoms, a cycloalkyl having from 3 to 6 carbon atoms, benzoyl or phenyl; and X is O, S or NR4 where R4 is hydrogen, an alkyl having from 1 to 4 carbon atoms, cyano, amino, nitro or acylamino; Or pharmaceutically acceptable acid addition salts thereof. Also disclosed is a process of preparing these compounds which comprises condensing an appropriate 4,5,6,7-tetrahydroimidazo-[4,5-c]-pyridine with an appropriate alkyl isocyanate, alkyl isothiocyanate or substituted S-methyl thiourea, preferably in a solvent such as ethanol, acetonitrile or dioxane, usually under reflux for from 4 to 12 hours. The products can be isolated by crystallization as free bases or as salts of pharmaceutically acceptable acids. The new compounds have proved to be well tolerated and to inhibit both the number of experimental ulcers and the gastric secretion in experimental animals. Thus, they should prove useful in the therapy of gastric and duodenal ulcers in man.